Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Treatment-Related Morbidity and Mortality Associated with Remission Induction in Adolescent and Young Adult (AYA) Versus Young Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Cory Michael Vela, PharmD, Viet Q. Ho, PharmD, RPh, BCOP, Justina Ofori Frimpong, PharmD, BCOP, Bryan Brinda, Pharm.D., Timothy George, Pharm.D., BCOP, Kendra L. Sweet, MD, Eric Padron, MD, David Sallman, MD, Alan F List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 5167.

https://doi.org/10.1182/blood.V128.22.5167.5167

Published: 2016

Journal Articles

Inferior Outcomes with Intensive AML Induction Therapy in Patients Age 70 or Greater Compared to Age 60-69

Bryan Brinda, Pharm.D., Viet Q. Ho, PharmD, RPh, BCOP, Timothy George, Pharm.D., BCOP, Jeffrey E Lancet, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 3750.

https://doi.org/10.1182/blood.V126.23.3750.3750

Published: 2015

Journal Articles

Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

Jose D Sandoval-Sus, MD, Julio C Chavez, MD, Samir Dalia, MD, Celeste M. Bello, MD, Bijal D. Shah, MD, Viet Q. Ho, PharmD, RPh, BCOP, Lisa Nodzon, PhDANP, Mohamed A. Kharfan-Dabaja, MD, Eduardo M. Sotomayor, MD, Lubomir Sokol, MD PhD, Javier Pinilla-Ibarz

Blood (2015) 126 (23): 2945.

https://doi.org/10.1182/blood.V126.23.2945.2945

Published: 2015

Journal Articles

Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings

Timothy E. Kubal, MD MBA, Christopher Rodriguez Salamanca, PA, Julio C Chavez, MD, Bijal D. Shah, MD, Rami S. Komrokji, MD, Viet Q. Ho, PharmD, RPh, BCOP, Jeffrey E Lancet, MD

Blood (2015) 126 (23): 5604.

https://doi.org/10.1182/blood.V126.23.5604.5604

Published: 2015

Journal Articles

Is There a Preferred Infusional Regimen for Patients with Relapsed/Refractory Multiple Myeloma?

Patrick T. Griffin, MD, Viet Q. Ho, PharmD, BCOP, William Fulp, Taiga Nishihori, MD, Kenneth H. Shain, MD PhD, Melissa Alsina, MD, Rachid Baz, MD

Blood (2014) 124 (21): 4757.

https://doi.org/10.1182/blood.V124.21.4757.4757

Published: 2014

Journal Articles

A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin

Viet Q. Ho, PharmD, BCOP, Robert Cade, PharmD, Gene A. Wetzstein, PharmD, BCOP, Van D Hoang, PharmD, BCOP, Alan List, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 3951.

https://doi.org/10.1182/blood.V122.21.3951.3951

Published: 2013

Journal Articles

Evidence for Selective Benefit of Sequential Treatment with Azanucleosides in Patients with Myelodysplastic Syndromes (MDS)

Susmitha Apuri, MD, Jeffrey E Lancet, MD, Najla H Al Ali, Eric Padron, MD, Viet Q. Ho, PharmD, BCOP, Javier Pinilla-Ibarz, MD, PhD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 4937.

https://doi.org/10.1182/blood.V120.21.4937.4937

Published: 2012

Journal Articles

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.

Asmita Mishra, MD, Jeffrey E Lancet, MD, Najla H Al Ali, Eric Padron, MD, Viet Q. Ho, PharmD, BCOP, Bryan J Little, Javier Pinilla-Ibarz, MD, PhD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 2815.

https://doi.org/10.1182/blood.V120.21.2815.2815

Published: 2012

Journal Articles

Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma

Viet Q. Ho, PharmD, BCOP, Elizabeth Finley-Oliver, RN, Kenneth H. Shain, MD, PhD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, Rachid Baz, MD

Blood (2011) 118 (21): 5142.

https://doi.org/10.1182/blood.V118.21.5142.5142

Published: 2011

Journal Articles

Rapid Infusion Rituximab in Maintenance Therapy: Is It Feasible?

Jolly R Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Melissa L. Teichman, PharmD, BCOP, Lubomir Sokol, MD, PhD, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Eduardo M. Sotomayor, Gene A. Wetzstein, PharmD, BCOP

Blood (2011) 118 (21): 4973.

https://doi.org/10.1182/blood.V118.21.4973.4973

Published: 2011

Journal Articles

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth H. Shain, MD, PhD, Daniel Sullivan, MD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, William Dalton, PhD, MD, Rachid Baz, MD

Blood (2011) 118 (21): 3979.

https://doi.org/10.1182/blood.V118.21.3979.3979

Published: 2011

Journal Articles

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Rachid Baz, MD, Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth Shain, MD, PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Jose Leonel Ochoa-Bayona, M.D., Daniel Sullivan, MD, Benjamin Djulbegovic, MD, PhD, William S. Dalton, PhD, MD

Blood (2011) 118 (21): 1878.

https://doi.org/10.1182/blood.V118.21.1878.1878

Published: 2011

Journal Articles

Efficacy of Ofatumumab and High-Dose Methylprednisolone for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Melissa L. Teichman, PharmD, BCOP, Viet Q. Ho, PharmD, BCOP, Lodovico Balducci, MD, Celeste M. Bello, MD, Javier Pinilla-Ibarz, M.D., Ph.D.

Blood (2011) 118 (21): 4619.

https://doi.org/10.1182/blood.V118.21.4619.4619

Published: 2011

Journal Articles

Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience

Heather Barnes Pound, PharmD, BCPS, Viet Q. Ho, PharmD, BCOP, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Martine Extermann, MD, PhD, Jeffrey E. Lancet, MD, Eduardo M. Sotomayor, Javier Pinilla-Ibarz, MD, PhD

Blood (2011) 118 (21): 4620.

https://doi.org/10.1182/blood.V118.21.4620.4620

Published: 2011

Journal Articles

Efficacy of Azacitidine In the Treatment of Chronic Myelomonocytic Leukemia

Melissa L. Teichman, PharmD, Gene A. Wetzstein, PharmD, BCOP, Viet Q. Ho, PharmD, BCOP, Jeffrey E. Lancet, MD, Alan F. List, Rami S. Komrokji, MD

Blood (2010) 116 (21): 4017.

https://doi.org/10.1182/blood.V116.21.4017.4017

Published: 2010

Journal Articles

Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions

Rebecca Tombleson, Viet Q. Ho, PharmD, BCOP, Eduardo M. Sotomayor, MD, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Javier Pinilla-Ibarz, MD, Lubomir Sokol, MD, PhD, Gene A. Wetzstein, PharmD, BCOP

Blood (2010) 116 (21): 4370.

https://doi.org/10.1182/blood.V116.21.4370.4370

Published: 2010

Journal Articles

A Retrospective Study of Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Lack of Response Observed In a Heavily Pretreated Population

Timothy J George, PharmD, BCOP, Joseph E Woolery, PharmD, Gene A. Wetzstein, PharmD, BCOP, Viet Q. Ho, PharmD, BCOP, Jeffrey E. Lancet, MD, Alan F. List, Rami S. Komrokji, MD

Blood (2010) 116 (21): 2186.

https://doi.org/10.1182/blood.V116.21.2186.2186

Published: 2010

Journal Articles

Albumin Is a Prognostic Factor for Response and Overall Survival in Relapsed or Refractory Acute Myeloid Leukemia (AML).

Rami S. Komrokji, MD, Mohamed A Kharfan-Dabaja, MD, Samantha L Price, PharmD, Gene A Wetzstein, PharmD, Alan F List, MD, Hugo F. Fernandez, MD, Timothy J. George, PharmD, Javier Pinilla-Ibarz, MD, PhD, Viet Q. Ho, PharmD, Jeffrey E Lancet, MD

Blood (2009) 114 (22): 4685.

https://doi.org/10.1182/blood.V114.22.4685.4685

Published: 2009

Journal Articles

Comparable Efficacy and Safety with Voriconazole or Posaconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.

Gene A Wetzstein, PharmD, BCOP, Timothy J. George, PharmD, BCOP, Mahsa Sharifi, PharmD, Van D Hoang, PharmD, BCOP, Viet Q Ho, PharmD, BCOP, Rod E Quilitz, PharmD, BCOP, Dana A Spears, PharmD, BCOP, Rami S. Komrokji, MD, Alan F List, MD, Jeffrey E Lancet, MD, John N Greene, MD

Blood (2009) 114 (22): 2059.

https://doi.org/10.1182/blood.V114.22.2059.2059

Published: 2009

Journal Articles

Salvage Chemotherapy Regimens for Acute Myeloid Leukemia: Is One Better?.

Samantha L Price, PharmD, Timothy J. George, PharmD, Gene A Wetzstein, PharmD, Jeffrey E Lancet, MD, Alan F. List, MD, Viet Q. Ho, PharmD, Hugo F. Fernandez, MD, Javier Pinilla-Ibarz, MD, PhD, Mohamed A Kharfan-Dabaja, MD, Rami S. Komrokji, MD

Blood (2009) 114 (22): 1022.

https://doi.org/10.1182/blood.V114.22.1022.1022

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Treatment-Related Morbidity and Mortality Associated with Remission Induction in Adolescent and Young Adult (AYA) Versus Young Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Inferior Outcomes with Intensive AML Induction Therapy in Patients Age 70 or Greater Compared to Age 60-69

Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings

Is There a Preferred Infusional Regimen for Patients with Relapsed/Refractory Multiple Myeloma?

A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin

Evidence for Selective Benefit of Sequential Treatment with Azanucleosides in Patients with Myelodysplastic Syndromes (MDS)

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.

Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma

Rapid Infusion Rituximab in Maintenance Therapy: Is It Feasible?

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Efficacy of Ofatumumab and High-Dose Methylprednisolone for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience

Efficacy of Azacitidine In the Treatment of Chronic Myelomonocytic Leukemia

Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions

A Retrospective Study of Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Lack of Response Observed In a Heavily Pretreated Population

Albumin Is a Prognostic Factor for Response and Overall Survival in Relapsed or Refractory Acute Myeloid Leukemia (AML).

Comparable Efficacy and Safety with Voriconazole or Posaconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.

Salvage Chemotherapy Regimens for Acute Myeloid Leukemia: Is One Better?.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only